GGHC
OCUL icon

Gilder Gagnon Howe & Co’s Ocular Therapeutix OCUL Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-45,150
Closed -$223K – 281
2016
Q2 		$223K Buy
+45,150
New +$447K ﹤0.01% 225

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Gilder Gagnon Howe & Co's OCUL Position: Q3 2016 in Review

Gilder Gagnon Howe & Co sold out of Ocular Therapeutix (OCUL) in Q3 2016, closing a stake of 45,150 shares — an estimated $223K sold.

Gilder Gagnon Howe & Co first reported a position in OCUL in Q2 2016 and held it in 1 quarter. The position peaked at $223K in Q2 2016. 72 funds tracked by Wall St. Rank hold OCUL as of Q3 2016.

  • Gilder Gagnon Howe & Co reported no remaining Ocular Therapeutix position as of Q3 2016 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 45,150 Ocular Therapeutix shares in Q3 2016, an estimated $223K.
  • Gilder Gagnon Howe & Co first reported a position in Ocular Therapeutix in Q2 2016 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Ocular Therapeutix position peaked at $223K in Q2 2016.
  • 72 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2016.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2016, filed 1 Nov 2016.